Open access
Open access
Powered by Google Translator Translator

Allergy & Immunology

What can we expect from first-generation COVID-19 vaccines?

22 Sep, 2020 | 10:02h | UTC

What can we expect from first-generation COVID-19 vaccines? – The Lancet

 

Commentary on Twitter

 


Editorial: Convalescent plasma for Covid-19

20 Sep, 2020 | 21:29h | UTC

Convalescent plasma for covid-19 – The BMJ

 

Commentary on Twitter

 


Covid-19: Do many people have pre-existing immunity?

18 Sep, 2020 | 09:41h | UTC

Covid-19: Do many people have pre-existing immunity? – The BMJ

 

Commentary on Twitter

 


Change in antibodies to SARS-CoV-2 over 60 days among health care personnel

18 Sep, 2020 | 09:32h | UTC

Change in Antibodies to SARS-CoV-2 Over 60 Days Among Health Care Personnel in Nashville, Tennessee -JAMA

 

Commentary on Twitter

 


[Press release – not published yet] Eli Lilly reports first, promising results for an antibody against COVID-19

17 Sep, 2020 | 09:28h | UTC

Eli Lilly reports first, promising results for an antibody against COVID-19 – Science

Press release: Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting

 


Multisystem effects of COVID-19: A concise review for practitioners

16 Sep, 2020 | 09:14h | UTC

Multisystem effects of COVID-19: A concise review for practitioners – Postgraduate Medicine

 


The lasting misery of coronavirus long-haulers

15 Sep, 2020 | 09:05h | UTC

The lasting misery of coronavirus long-haulers – Nature

 


Viewpoint: COVID-19 and the path to immunity

14 Sep, 2020 | 01:20h | UTC

COVID-19 and the Path to Immunity – JAMA

 

Commentary on Twitter

 


COVID-19 herd immunity: Where are we?

14 Sep, 2020 | 01:18h | UTC

COVID-19 herd immunity: where are we? – Nature Reviews Immunology

 

Commentary on Twitter

 


The underdog coronavirus vaccines that the world will need if front runners stumble

11 Sep, 2020 | 01:20h | UTC

The underdog coronavirus vaccines that the world will need if front runners stumble – Nature

 


A leading coronavirus vaccine trial is on hold: Scientists react

10 Sep, 2020 | 09:43h | UTC

A leading coronavirus vaccine trial is on hold: scientists react – Nature

 


Opinion: Halting the Oxford vaccine trial doesn’t mean it’s not safe – it shows they’re following the right process

10 Sep, 2020 | 09:42h | UTC

Halting the Oxford vaccine trial doesn’t mean it’s not safe – it shows they’re following the right process

See also: Expert reaction to pausing of Oxford vaccine trial due to participant falling ill – Science Media Centre

 


‘Everyone was left to guess what went wrong’: An open letter to AstraZeneca’s CEO on transparency

10 Sep, 2020 | 09:40h | UTC

‘Everyone was left to guess what went wrong’: An open letter to AstraZeneca’s CEO on transparency – STAT

 

Commentary on Twitter

 


AstraZeneca Covid-19 vaccine study put on hold due to suspected adverse reaction in participant in the U.K.

9 Sep, 2020 | 09:45h | UTC

AstraZeneca Covid-19 vaccine study put on hold due to suspected adverse reaction in participant in the U.K. – STAT

 

Commentary on Twitter

 


[Preprint] Randomized trial: Convalescent plasma not associated with improved outcomes in Covid-19

9 Sep, 2020 | 09:41h | UTC

Convalescent plasma in the management of moderate COVID-19 in India: An open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial) – medRxiv

 

Commentary on Twitter

 


Perspective: “When will WE have a vaccine?” — understanding questions and answers about Covid-19 vaccination

9 Sep, 2020 | 09:37h | UTC

“When Will We Have a Vaccine?” — Understanding Questions and Answers about Covid-19 Vaccination – New England Journal of Medicine

 

Commentary on Twitter

 


The coronavirus is mutating — does it matter?

9 Sep, 2020 | 09:35h | UTC

The coronavirus is mutating — does it matter? – Nature

 


The immunology of multisystem inflammatory syndrome in children with COVID-19

9 Sep, 2020 | 09:33h | UTC

The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19 – Cell

 


An ethical framework for global vaccine allocation

8 Sep, 2020 | 01:24h | UTC

An ethical framework for global vaccine allocation – Science

Commentary: Who should get the COVID-19 vaccine first? – University of Pennsylvania School of Medicine

 

Commentaries on Twitter

 


WHO: Emergency use approval is a “temporary solution,” countries should wait for large clinical trials to finish to roll out a COVID-19 vaccine en masse

8 Sep, 2020 | 01:21h | UTC

Emergency Use Approval Is A “Temporary Solution,” Countries Should Wait For Large Clinical Trials To Finish To Roll Out A COVID-19 Vaccine En Masse – Health Policy Watch

 


Evolution of the COVID-19 vaccine development landscape

8 Sep, 2020 | 01:18h | UTC

Evolution of the COVID-19 vaccine development landscape – Nature Reviews Drug Discovery

 


COVID-19 is, in the end, an endothelial disease

8 Sep, 2020 | 01:11h | UTC

COVID-19 is, in the end, an endothelial disease – European Heart Journal

 

Commentary on Twitter

 


Post-COVID syndrome severely damages children’s hearts; ‘immense inflammation’ causing cardiac blood vessel dilation

6 Sep, 2020 | 22:03h | UTC

Post-COVID syndrome severely damages children’s hearts; ‘immense inflammation’ causing cardiac blood vessel dilation – University of Texas Health Science Center at San Antonio

Original Study: Multisystem inflammatory syndrome in children: A systematic review – EClinicalMedicine

 

Commentary on Twitter

 


Does the COVID-19 cytokine storm exist?

6 Sep, 2020 | 21:55h | UTC

Does the COVID-19 cytokine storm exist? – Radboud University Medical Center

Original Study: Cytokine Levels in Critically Ill Patients With COVID-19 and Other Conditions – JAMA

 

Commentary on Twitter

 


Russian coronavirus vaccine results have been published

6 Sep, 2020 | 21:48h | UTC

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia – The Lancet

Commentaries: COVID-19 vaccines: early success and remaining challenges – The Lancet AND The Russian vaccine for COVID-19 – The Lancet Respiratory Medicine AND Early-phase Russian trials reveal safety and immunogenicity of two formulations of a two-part vaccine – News Medical / The Lancet AND Russian coronavirus vaccine results have been published – here’s what they reveal – The Conversation

 

Commentary on Twitter

 


Stay Updated in Your Specialty

 

No spam, just news.